ucihealth.org
Medical Oncology, Internal Medicine
gastrointestinal cancers, esophageal cancer, gastric cancer, colorectal cancer, anal carcinomas, pancreatic cancer, liver cancer, bile duct cancer, neuroendocrine tumors
Dr. Farshid Dayyani is a board-certified UCI Health medical oncologist who specializes in the treatment of gastrointestinal and hepatobiliary malignancies. His clinical interests include colorectal, esophageal, stomach, liver, bile duct, pancreatic and neuroendocrine cancers, as well as anal carcinoma.
He earned a combined medical degree and PhD in immunology at Ludwig Maximilian University of Munich in Germany. He completed a research fellowship in cancer biology and an internal medicine residency at Harvard Medical School in Boston, Mass. Next, he completed a combined clinical and research fellowship in medical oncology at the University of Texas MD Anderson Cancer Center in Houston. He later served as global clinical lead for oncology at Roche Diagnostics.
Dayyani serves as medical director of the Stern Center for Clinical Trials & Research and associate director for translational science for the Chao Family Comprehensive Cancer Center. His research focus is on innovative clinical and translational studies of gastrointestinal and hepatobiliary carcinomas with the goal of bringing leading-edge treatments to patients.
He manages a wide portfolio of investigator-initiated, National Cancer Institute-funded and industry sponsored clinical trials aimed at developing novel treatment options and establishing new biomarkers. He is also the author or co-author of more than 100 research studies published in leading medical journals.
Dayyani — who also speaks German and Farsi — sees patients at the UCI Health Chao Family Comprehensive Cancer Center and UCI Health Cancer Center — Newport.
